Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab for Dyslipidemia in Nephrotic Syndrome
NCT03004001Phase 2Terminated
- Start
- Jan 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia comparing Alirocumab and atorvastatin with Alirocumab placebo and atorvastatin (2 arms). Primary endpoint: Levels of plasma lipoproteins at 10 months. Started Jan 2017; status: terminated.
02
Drugs
alirocumab
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03004001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004001.